Top

Virology Journal

Published in:

Open Access 01-12-2011 | Research

Viral and cellular requirements for the budding of Feline Endogenous Retrovirus RD-114

Authors: Aiko Fukuma, Masumi Abe, Shuzo Urata, Rokusuke Yoshikawa, Yuko Morikawa, Takayuki Miyazawa, Jiro Yasuda

Published in: Virology Journal | Issue 1/2011

Abstract

Background

RD-114 virus is a feline endogenous retrovirus and produced as infectious viruses in some feline cell lines. Recently, we reported the contamination of an infectious RD-114 virus in a proportion of live attenuated vaccines for dogs and cats. It is very difficult to completely knock out the RD-114 proviruses from cells, as endogenous retroviruses are usually integrated multiply into the host genome. However, it may be possible to reduce the risk of contamination of RD-114 virus by regulating the viral release from cells.

Results

In this study, to understand the molecular mechanism of RD-114 virus budding, we attempted to identify the viral and cellular requirements for RD-114 virus budding. Analyses of RD-114 L-domain mutants showed that the PPPY sequence in the pp15 region of Gag plays a critical role in RD-114 virus release as viral L-domain. Furthermore, we investigated the cellular factors required for RD-114 virus budding. We demonstrated that RD-114 virus release was inhibited by overexpression of dominant negative mutants of Vps4A, Vps4B, and WWP2.

Conclusions

These results strongly suggest that RD-114 budding utilizes the cellular multivesicular body sorting pathway similar to many other retroviruses.

Available only for authorised users

Fischinger PJ, Peebles PT, Nomura S, Haapala DK: Isolation of RD-114-like oncornavirus from a cat cell line. J Virol 1973, 11: 978-985.PubMedCentralPubMed

McAllister RM, Nicolson M, Gardner MB, Rongey RW, Rasheed S, Sarma PS, Huebner RJ, Hatanaka M, Oroszlan S, Gilden RV, et al.: C-type virus released from cultured human rhabdomyosarcoma cells. Nat New Biol 1972, 235: 3-6.CrossRefPubMed

Okabe H, Gilden RV, Hatanaka M: RD 114 virus-specific sequences in feline cellular RNA: detection and characterization. J Virol 1973, 12: 984-994.PubMedCentralPubMed

van der Kuyl AC, Dekker JT, Goudsmit J: Discovery of a new endogenous type C retrovirus (FcEV) in cats: evidence for RD-114 being an FcEV(Gag-Pol)/baboon endogenous virus BaEV(Env) recombinant. J Virol 1999, 73: 7994-8002.PubMedCentralPubMed

Okada M, Yoshikawa R, Shojima T, Baba K, Miyazawa T: Susceptibility and production of a feline endogenous retrovirus (RD-114 virus) in various feline cell lines. Virus Res 2011, 155: 268-273. 10.1016/j.virusres.2010.10.020CrossRefPubMed

Baumann JG, Gunzburg WH, Salmons B: CrFK feline kidney cells produce an RD114-like endogenous virus that can package murine leukemia virus-based vectors. J Virol 1998, 72: 7685-7687.PubMedCentralPubMed

Miyazawa T: Endogenous retroviruses as potential hazards for vaccines. Biologicals: J Int Assoc Biol Standardization 2010, 38: 371-376.CrossRef

Miyazawa T, Yoshikawa R, Golder M, Okada M, Stewart H, Palmarini M: Isolation of an infectious endogenous retrovirus in a proportion of live attenuated vaccines for pets. J Virol 2010, 84: 3690-3694. 10.1128/JVI.02715-09PubMedCentralCrossRefPubMed

Yoshikawa R, Sato E, Miyazawa T: Contamination of infectious RD-114 virus in vaccines produced using non-feline cell lines. Biologicals 2011, 39: 33-37. 10.1016/j.biologicals.2010.11.001CrossRefPubMed

10.

Bieniasz PD: Late budding domains and host proteins in enveloped virus release. Virology 2006, 344: 55-63. 10.1016/j.virol.2005.09.044CrossRefPubMed

11.

Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, et al.: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107: 55-65. 10.1016/S0092-8674(01)00506-2CrossRefPubMed

12.

Kikonyogo A, Bouamr F, Vana ML, Xiang Y, Aiyar A, Carter C, Leis J: Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci USA 2001, 98: 11199-11204. 10.1073/pnas.201268998PubMedCentralCrossRefPubMed

13.

Martin-Serrano J, Eastman SW, Chung W, Bieniasz PD: HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J Cell Biol 2005, 168: 89-101.PubMedCentralCrossRefPubMed

14.

VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA: Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci USA 2001, 98: 7724-7729. 10.1073/pnas.131059198PubMedCentralCrossRefPubMed

15.

Yasuda J, Hunter E, Nakao M, Shida H: Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep 2002, 3: 636-640. 10.1093/embo-reports/kvf132PubMedCentralCrossRefPubMed

16.

Yasuda J, Nakao M, Kawaoka Y, Shida H: Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol 2003, 77: 9987-9992. 10.1128/JVI.77.18.9987-9992.2003PubMedCentralCrossRefPubMed

17.

Strack B, Calistri A, Craig S, Popova E, Gottlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003, 114: 689-699. 10.1016/S0092-8674(03)00653-6CrossRefPubMed

18.

Eastman SW, Martin-Serrano J, Chung W, Zang T, Bieniasz PD: Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. J Biol Chem 2005, 280: 628-636.CrossRefPubMed

19.

Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD: Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci USA 2003, 100: 12414-12419. 10.1073/pnas.2133846100PubMedCentralCrossRefPubMed

20.

Stuchell MD, Garrus JE, Muller B, Stray KM, Ghaffarian S, McKinnon R, Krausslich HG, Morham SG, Sundquist WI: The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem 2004, 279: 36059-36071. 10.1074/jbc.M405226200CrossRefPubMed

21.

Hurley JH, Emr SD: The ESCRT complexes: structure and mechanism of a membrane-trafficking network. Annu Rev Biophys Biomol Struct 2006, 35: 277-298. 10.1146/annurev.biophys.35.040405.102126PubMedCentralCrossRefPubMed

22.

Xu HM, Liao B, Zhang QJ, Wang BB, Li H, Zhong XM, Sheng HZ, Zhao YX, Zhao YM, Jin Y: Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem 2004, 279: 23495-23503. 10.1074/jbc.M400516200CrossRefPubMed

23.

Yeom YI, Fuhrmann G, Ovitt CE, Brehm A, Ohbo K, Gross M, Hubner K, Scholer HR: Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development 1996, 122: 881-894.PubMed

24.

Chen A, Gao B, Zhang J, McEwen T, Ye SQ, Zhang D, Fang D: The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Mol Cell Biol 2009, 29: 5348-5356. 10.1128/MCB.00407-09PubMedCentralCrossRefPubMed

25.

Urata S, Yasuda J: Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40. J Gen Virol 2010, 91: 228-234. 10.1099/vir.0.015495-0CrossRefPubMed

26.

Kolesnikova L, Strecker T, Morita E, Zielecki F, Mittler E, Crump C, Becker S: Vacuolar protein sorting pathway contributes to the release of Marburg virus. J Virol 2009, 83: 2327-2337. 10.1128/JVI.02184-08PubMedCentralCrossRefPubMed

27.

Fukuma A, Abe M, Morikawa Y, Miyazawa T, Yasuda J: Cloning and characterization of the antiviral activity of feline Tetherin/BST-2. PloS one 2011, 6: e18247. 10.1371/journal.pone.0018247PubMedCentralCrossRefPubMed

28.

Yoshikawa R, Sato E, Igarashi T, Miyazawa T: Characterization of RD-114 virus isolated from a commercial canine vaccine manufactured using CRFK cells. J Clin Microbiol 2010, 48: 3366-3369. 10.1128/JCM.00992-10PubMedCentralCrossRefPubMed

29.

Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J: Cellular factors required for Lassa virus budding. J Virol 2006, 80: 4191-4195. 10.1128/JVI.80.8.4191-4195.2006PubMedCentralCrossRefPubMed

30.

Yasuda J, Hunter E: A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol 1998, 72: 4095-4103.PubMedCentralPubMed

31.

Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J: Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009, 83: 2382-2385. 10.1128/JVI.01607-08PubMedCentralCrossRefPubMed

32.

Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J: Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J Virol 2007, 81: 4895-4899. 10.1128/JVI.02829-06PubMedCentralCrossRefPubMed

33.

Sakaguchi S, Baba K, Ishikawa M, Yoshikawa R, Shojima T, Miyazawa T: Focus assay on RD114 virus in QN10S cells. J Vet Med Sci 2008, 70: 1383-1386. 10.1292/jvms.70.1383CrossRefPubMed

Title: Viral and cellular requirements for the budding of Feline Endogenous Retrovirus RD-114
Authors: Aiko Fukuma
Masumi Abe
Shuzo Urata
Rokusuke Yoshikawa
Yuko Morikawa
Takayuki Miyazawa
Jiro Yasuda
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-8-540

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

Mutation of putative N-Linked Glycosylation Sites in Japanese encephalitis Virus Premembrane and Envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination

Evolutionary variation of papillomavirus E2 protein and E2 binding sites

Diagnosis and molecular characterization of rabies virus from a buffalo in China: a case report

The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials